A Multicenter, Double-Blind, Randomized, Escalating Dose-Ranging Study to Investigate the Safety and Immunogenicity of the VAX102 Influenza Vaccine in Healthy Adults

Trial Profile

A Multicenter, Double-Blind, Randomized, Escalating Dose-Ranging Study to Investigate the Safety and Immunogenicity of the VAX102 Influenza Vaccine in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs VAX 102 (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 27 May 2011 Results published in Vaccine.
    • 27 Oct 2008 Results presented at joint 48th ICAAC/46th IDSA meeting, held in Washington, DC, USA in October 2008, as reported in a media release from VaxInnate.
    • 25 Oct 2008 Results presented at ICAAC/IDSA 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top